4//SEC Filing
TAKEDA PHARMACEUTICAL CO LTD 4
Accession 0001395064-21-000216
$TAKCIK 0001840233other
Filed
Oct 25, 8:00 PM ET
Accepted
Oct 26, 8:31 PM ET
Size
12.1 KB
Accession
0001395064-21-000216
Insider Transaction Report
Form 4
Takeda Ventures, Inc.
10% Owner
Transactions
- Conversion
Common Stock
2021-10-26+1,475,121→ 1,475,121 total(indirect: See explanation) - Conversion
Series B Preferred Stock
2021-10-26−1,248,180→ 0 total(indirect: See explanation)→ Common Stock (1,248,180 underlying) - Conversion
Series C Preferred Stock
2021-10-26−226,941→ 0 total(indirect: See explanation)→ Common Stock (226,941 underlying)
TAKEDA PHARMACEUTICAL CO LTD
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2021-10-26−1,248,180→ 0 total(indirect: See explanation)→ Common Stock (1,248,180 underlying) - Conversion
Common Stock
2021-10-26+1,475,121→ 1,475,121 total(indirect: See explanation) - Conversion
Series C Preferred Stock
2021-10-26−226,941→ 0 total(indirect: See explanation)→ Common Stock (226,941 underlying)
Footnotes (3)
- [F1]Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuers Common Stock on a one-for-one basis immediately prior to the completion of the Issuers initial public offering for no additional consideration. The Preferred Stock had no expiration date.
- [F2]This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Takeda Ventures, Inc.
- [F3]The reportable securities are owned directly by Takeda Ventures, Inc. Takeda Pharmaceutical Company Limiteds beneficial ownership of these securities is comprised of the reportable securities owned by Takeda Ventures, Inc. Takeda Ventures, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Documents
Issuer
Xilio Therapeutics, Inc.
CIK 0001840233
Entity typeother
Related Parties
1- filerCIK 0001395064
Filing Metadata
- Form type
- 4
- Filed
- Oct 25, 8:00 PM ET
- Accepted
- Oct 26, 8:31 PM ET
- Size
- 12.1 KB